Immunonanotherapeutics Providing a Th1-Biased Response

• US 20110223201A1
• Filed: 04/21/2010
• Published: 09/15/2011
• Est. Priority Date: 04/21/2009
• Status: Abandoned Application

• Current Assignee: Selecta Biosciences, Inc. (Cartesian Therapeutics, Inc.)
• Original Assignee: Selecta Biosciences, Inc. (Cartesian Therapeutics, Inc.)
• Inventors: Lipford, Grayson B., Bratzler, Robert L.
• Application Number:
  US12/764,569
• Publication Number:
  US 20110223201A1
• Time in Patent Office: Days
• US Class Current: 424/400
• CPC Class Codes: A61K 47/593 Polyesters, e.g. PLGA or polylactide-co-glycolide
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/6935 the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
• CPC Class Codes: A61K 47/6937 the polymer being PLGA, PLA or polyglycolic acid
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 39/00 General protective or antinoxious agents
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1-biased immune response is desirable.

Claims

1. A composition for treatment of a condition comprising:

synthetic nanocarriers comprising (1) an immunofeature surface, and (2) a Th1 biasing immunostimulatory agent coupled to the synthetic nanocarriers; and

a pharmaceutically acceptable excipient;

wherein the immunofeature surface does not comprise antigen that is relevant to treatment of the condition in an amount sufficient to provoke an adaptive immune response to the antigen that is relevant to treatment of the condition.

2. The composition of claim 1, wherein the immunofeature surface comprises no antigen that is relevant to treatment of the condition.

3. The composition of claim 1, wherein the antigen that is relevant to treatment of the condition comprises an allergen.

4. The composition of claim 1, wherein the antigen that is relevant to treatment of the condition comprises a tumor antigen.

5. The composition of claim 1, wherein the antigen that is relevant to treatment of the condition comprises a chronic infectious agent antigen.

6. The composition of claim 1, wherein the immunofeature surface comprises a non-antigenic immunofeature surface.

7. The composition of claim 1, wherein the synthetic nanocarrier further comprises a T-cell antigen.

8. The composition of claim 1, wherein the synthetic nanocarriers comprise a polymeric matrix.

9. The composition of claim 1, wherein the Th1 biasing immunostimulatory agent comprises one or more of imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, and 1,2-bridged imidazoquinoline amine, CpG, immunostimulatory RNA, lipopolysacharide, VSV-G, or HMGB-1.

10. The composition of claim 1, wherein the immunofeature surface comprises nicotine and derivatives thereof, methoxy groups, positively charged amine groups, sialyllactose, and avidin and/or avidin derivatives, and residues of any of the above.

11. The composition of claim 1, wherein the synthetic nanocarriers comprise synthetic nanocarriers that are spheres, cubes, cylinders, cones, or pyramids.

12. The composition of claim 1, wherein a minimum dimension of at least 75% of the synthetic nanocarriers in a sample, based on a total number of synthetic nanocarriers in the sample, is greater than 100 nm.

13. The composition of claim 12, wherein the antigen that is relevant to treatment of the condition comprises an allergen.

14. The composition of claim 12, wherein the antigen that is relevant to treatment of the condition comprises a tumor antigen.

15. The composition of claim 12, wherein the antigen that is relevant to treatment of the condition comprises a chronic infectious agent antigen.

16. The composition of claim 12, wherein the immunofeature surface comprises a non-antigenic immunofeature surface.

17. The composition of claim 12, wherein the synthetic nanocarriers further comprise a T-cell antigen.

22. A method comprising:

administering the composition of claim 1 to a subject.

18-21. -21. (canceled)

23-41. -41. (canceled)

42. A method comprising:

identifying a subject suffering from a condition;

providing a composition that comprises synthetic nanocarriers that comprise (1) an APC targeting feature, and (2) a Th1 biasing immunostimulatory agent coupled to the synthetic nanocarriers; and

a pharmaceutically acceptable excipient; and

administering the composition to the subject;

wherein the administration of the composition does not further comprise co-administration of an antigen that is relevant to treatment of the condition.

43-56. -56. (canceled)

57. A method comprising:

providing a composition comprising synthetic nanocarriers that comprise a Th1 biasing immunostimulatory agent and an APC targeting feature;

administering the composition to a subject; and

administering an antigen to the subject to which a Th1 biased response is clinically beneficial at a time different from administration of the composition to the subject;

wherein administration of the antigen comprises passive administration or active administration.

58-68. -68. (canceled)